Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK plc filed a Form 6-K reporting a transaction notification dated September 04, 2025. The filing identifies the security by ISIN GB00BN7SWP63 and discloses an aggregated volume of 10,050 shares. The document provides the transaction date and quantity but does not state the transaction price, the identity of the reporting person or counterparty, or aggregated price information.
GSK plc reports a routine purchase of its ordinary shares under an existing buyback programme. On 03 September 2025 the Company, through Merrill Lynch International, purchased 232,912 ordinary shares at prices in the range shown in the schedule and will hold the purchased shares as Treasury shares. Since the non-discretionary agreement dated 4 June 2025, the Company has purchased 27,030,667 ordinary shares. After this trade the Company holds 245,165,050 ordinary shares in treasury and has 4,070,231,046 ordinary shares in issue (excluding treasury); total voting rights are 4,070,231,046 and the percentage of voting rights attributable to treasury shares is 6.02%.
GSK plc announced that, acting through Merrill Lynch International, it purchased 296,202 ordinary shares of 31 3/4 pence each on 02 September 2025 at prices between 1,440.50p and 1,469.00p. The purchased shares will be held as treasury stock and form part of the company’s existing buyback programme under a non-discretionary agreement with the broker signed 4 June 2025. Since 4 June 2025 the company has bought 26,797,755 ordinary shares. After this transaction GSK will hold 244,932,138 shares in treasury, have 4,070,463,958 ordinary shares in issue excluding treasury shares, and a total number of voting rights of 4,070,463,958. The company reports that treasury shares represent 6.02% of voting rights following the purchase.
GSK plc reported a transaction in own shares under its announced buyback programme. Acting through Merrill Lynch International on 01 September 2025 the Company purchased 227,465 ordinary shares at prices between 1,442.00p and 1,468.50p per share; the aggregated lowest and highest reported prices on the day were 1,451.50p and 1,468.50p respectively. The purchased shares will be held as treasury shares and form part of the non-discretionary agreement with the Broker entered into on 4 June 2025. Since 4 June 2025 the Company has purchased 26,501,553 ordinary shares. Following this purchase the Company will hold 244,635,936 shares in treasury, have 4,070,760,160 ordinary shares in issue (excluding treasury) and treasury shares represent 6.01% of voting rights.
GSK plc reports its issued share capital and total voting rights as of 31 August 2025. The company had 4,315,396,096 Ordinary Shares of 31 pence each, of which 244,408,471 were held in Treasury, leaving a total of 4,070,987,625 voting rights. Shareholders may use this figure as the denominator to determine whether they must notify changes in their holdings under the FCA Disclosure Guidance and Transparency Rules.
GSK plc announced a purchase of 252,588 ordinary shares on 29 August 2025 as part of its ongoing buyback programme executed by Merrill Lynch International. The filing lists a lowest price of 1,447.00p, a highest price of 1,461.50p and an average price of 1,454.14p for that trading day. Since the non-discretionary agreement began on 4 June 2025 the Company has purchased 26,274,088 ordinary shares. Following this transaction GSK will hold 244,408,471 shares in treasury, have 4,070,987,625 ordinary shares in issue (excluding treasury) and total voting rights of 4,070,987,625. The filing also states treasury shares represent 6.00% of voting rights following the purchase.
GSK plc reports purchases of its ordinary shares under its ongoing buyback programme. On 28 August 2025 the company, acting through broker Merrill Lynch International, acquired 236,167 ordinary shares of 31.25 pence each with a reported lowest price of 1,460.50p, highest price of 1,479.00p and an average/aggregate price shown as 1,466.11p. The purchased shares will be held as treasury shares and the announcement confirms this forms part of the non-discretionary agreement with the broker entered into on 4 June 2025. Since that agreement the Company has purchased 26,021,500 ordinary shares. After the 28 August purchase GSK will hold 244,155,883 shares in treasury and have 4,071,236,744 ordinary shares in issue (excluding treasury), giving a total number of voting rights of 4,071,236,744 and treasury shares representing 6.00% of voting rights. Detailed trade-level execution data across the London Stock Exchange and CBOE Europe are included.
GSK plc purchased 260,986 ordinary shares on 27 August 2025 through Merrill Lynch International as part of its existing buyback programme. The trades were executed on the London Stock Exchange (and reported across recognised venues) at prices between 1,471.00p and 1,484.00p, with an aggregated average price reported as 1,477.76p. Since the non-discretionary broker agreement of 4 June 2025, the Company has bought 25,785,333 ordinary shares. After this transaction GSK will hold 243,919,716 shares in treasury and will have 4,071,472,911 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,071,472,911, and treasury shares represent 5.99% of voting rights.
GSK plc reports that, acting through Merrill Lynch International, it purchased 251,452 ordinary shares of 31.75p each on 26 August 2025 under its ongoing buyback programme. Since the non-discretionary agreement dated 4 June 2025, the Company has purchased a total of 25,524,347 ordinary shares. Following the latest purchase the Company will hold 243,658,730 ordinary shares in treasury and have 4,071,733,897 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,071,733,897, and the percentage of voting rights attributable to treasury shares is reported as 5.98%.
GSK plc reports on 22 August 2025 that, acting through its corporate broker Merrill Lynch International under a non-discretionary agreement entered into on 4 June 2025, it purchased 243,639 ordinary shares for holding as Treasury shares as part of its existing buyback programme. Since 4 June 2025 the company has purchased a total of 25,272,895 ordinary shares. After this purchase GSK will hold 243,407,278 ordinary shares in treasury and have 4,071,985,349 ordinary shares in issue (excluding Treasury shares). The total number of voting rights is 4,071,985,349 and the percentage of voting rights attributable to ordinary shares held in treasury is 5.98%.